GLYCTK-AS1

Across TCGA pan-cancer cohorts, GLYCTK-AS1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of GLYCTK-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where GLYCTK-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GLYCTK-AS1 is over-expressed in tumor, although a few such as LUSC and BRCA show the opposite, repressed pattern.

LIHC, COAD, and STAD are the cancer types where GLYCTK-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GLYCTK-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.125	<.001	5	view →
COAD	Male	II,III,IV	+0.227	.001	4	view →
STAD	All	II,III,IV	+0.197	.007	4	view →
LUSC	Male	All	−0.144	.001	4	view →
KICH	All	II,III,IV	+0.208	.024	2	view →
BLCA	Female	All	+0.158	.040	2	view →
PRAD	All	All	+0.158	.004	2	view →
BRCA	All	III,IV	−0.102	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

GLYCTK-AS1–LIHC

Open the LIHC breakdown →